
CXCR2-IN-1
CAS No. 1873376-49-8
CXCR2-IN-1( —— )
Catalog No. M12902 CAS No. 1873376-49-8
A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 258 | Get Quote |
![]() ![]() |
10MG | 372 | Get Quote |
![]() ![]() |
25MG | 623 | Get Quote |
![]() ![]() |
50MG | 887 | Get Quote |
![]() ![]() |
100MG | 1197 | Get Quote |
![]() ![]() |
500MG | 2394 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCXCR2-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6.
-
DescriptionA potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6; has developability profiles (CYP inhibition pIC<5.0, and hERG binding affinity pIC<4.0); exhibits favorable PK profile, reasonable CNS penetration, and good developability potential; orally bioavailable.
-
In VitroCXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 (compound 22) shows favorable central nervous system penetration property (Br/Bl>0.45).
-
In VivoCXCR2-IN-1 shows efficacy in a cuprizone-induced demyelination model through oral administration, providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseases such as multiple sclerosis.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1873376-49-8
-
Formula Weight476.3492032
-
Molecular FormulaC19H20Cl2FN3O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥5.4 mg/mL (Need ultrasonic and warming)
-
SMILESCN1CCC(CC1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl
-
Chemical NameUrea, N-(2-chloro-3-fluorophenyl)-N'-[4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xu H, et al. ACS Med Chem Lett. 2016 Feb 8;7(4):397-402.
molnova catalog



related products
-
Ladarixin sodium
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
-
SX-517
A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.
-
GW-766994
GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist.